06:03:43 EDT Fri 29 Mar 2024
Enter Symbol
or Name
USA
CA



IntelliPharmaCeutics International Inc
Symbol IPCI
Shares Issued 43,537,849
Close 2018-05-22 C$ 0.52
Market Cap C$ 22,639,681
Recent Sedar Documents

IntelliPharma receives Nasdaq delisting reprieve

2018-05-22 16:09 ET - News Release

Mr. Andrew Patient reports

NASDAQ HEARINGS PANEL GRANTS INTELLIPHARMACEUTICS' REQUEST FOR CONTINUED LISTING

IntelliPharmaCeutics International Inc. has received notice from the Nasdaq hearings panel granting its request for continued listing until Sept. 28, 2018, while the company works to regain compliance with Nasdaq requirements.

At a hearing held on May 17, 2018, the company presented its plan to regain and maintain compliance with Nasdaq's continued listing requirements. The panel granted the company's request for continued listing, subject to conditions. On or before Sept. 28, 2018, the company must comply with the $1 bid price requirement by having a closing bid price of over $1 for 10 prior consecutive trading days. The company must also have by Sept. 28, 2018, a stockholders equity position of over $2.5-million. Finally, the company must by that date provide the panel with updated financial projections demonstrating its ability to maintain compliance with the stockholders equity rule for the coming year. There is no assurance that the company will be able to regain compliance with the Nasdaq requirements, or if it does, that the company will be able to maintain such compliance.

About IntelliPharmaCeutics International Inc.

IntelliPharmaCeutics is a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. The company's patented Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to a wide range of existing and new pharmaceuticals.

We seek Safe Harbor.

© 2024 Canjex Publishing Ltd. All rights reserved.